Thermo Fisher Scientific (NYSE:TMO) Upgraded at Wall Street Zen

Posted by Brian Himes on Oct 6th, 2026

Wall Street Zen upgraded shares of Thermo Fisher Scientific (NYSE:TMO – Free Report) from a hold rating to a buy rating in a research note published on Saturday morning,Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the stock. Jefferies Financial Group restated a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Scotiabank initiated coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They set an “outperform” rating for the company. BMO Capital Markets lowered shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. Finally, Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $628.78.

View Our Latest Research Report on TMO

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $675.47 on Friday. The stock has a market cap of $249.75 billion, a PE ratio of 36.33, a price-to-earnings-growth ratio of 2.74 and a beta of 0.87. Thermo Fisher Scientific has a 52 week low of $435.27 and a 52 week high of $683.63. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company’s 50-day moving average price is $620.96 and its two-hundred day moving average price is $536.59.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Polaris Financial Partners acquired a new stake in Thermo Fisher Scientific in the third quarter worth about $32,000. Kilter Group LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Legacy Wealth Managment LLC ID raised its stake in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the last quarter. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $26,000. Finally, MBM Wealth Consultants LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $29,000. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.